Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations. The current paradigm in genetic medicine relies on developing independent therapies for each separate mutation in the patient population. Founded by pioneers in the CRISPR field from leading institutions for gene editing research, the company is developing a first-of-its-kind RNA writing platform capable of editing thousands of diverse mutations across patients with a single product.
Company Details
- Employees
- 21
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.amber.bio/
- Keywords
- New York.
Amber Bio Questions
Amber Bio's website is https://www.amber.bio/
Amber Bio's LinkedIn profile is https://www.linkedin.com/company/amber-bio
Amber Bio has
21 employees.
View email and phone details for 21
employees at Amber Bio.
Amber Bio's industry is
Pharmaceutical Manufacturing
Amber Bio's top competitors are
Inceptive,
Scribio,
Octant,
Synonym,
Nitra,
Xaira Therapeutics,
Arda Therapeutics,
Denali Therapeutics,
Coral (Acquihired),
Taxa.
Amber Bio's categories are Pharmaceutical Manufacturing
